China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan

February 25, 2009

HARBIN, China, Feb. 25 /PRNewswire-Asia-FirstCall/ — China Sky One
Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company producing
over-the-counter drugs in the People’s Republic of China (“PRC”), today
announced that its wholly owned subsidiary, Harbin Tian Di Ren Medical Science
and Technology Company, has expanded the sale of its Sumei Slim Patch into
South Korea and Sudan. As a result, the product is now available in 26
countries and regions.

Following three months of market research, discussions and negotiations,
China Sky One Medical has engaged PAX¡Â¤Medicare and Lai Li Investment Company
as exclusive sales agents for the Sumei Slim Patch in South Korea and Sudan,
respectively. The Slim Patch has passed the necessary examinations required in
both countries and will be available to consumers shortly. China Sky One
Medical’s international sales team, PAX-Medicare and Lai Li Investment Company,
is currently developing a detailed marketing plan that includes sales
projections for the Slim Patch in both South Korea and in Sudan.

The Sumei Slim Patch is a proprietary weight loss product. Its main
ingredients are extracted from Chinese herbs, which are healthy, natural and
free of harmful side effects. Due to its effectiveness and safety, the Sumei
Slim Patch is one of China Sky One Medical’s best-selling products, and has
received accolades from consumers in China and in other countries.

“We are pleased to expand sales of the Sumei Slim Patch into South Korea
and Sudan, which is a testament to the product’s popularity and strong market
potential,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.
“It is well known that South Koreans spend money on keeping in shape, and we
expect Sumei Slim Patch to perform well in these countries and create value
for both consumers and shareholders.”

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology
Company (“TDR”), Harbin First Bio- Engineering Company Limited (“First”),
Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin
Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and
distributes over-the-counter pharmaceutical products, which make up its major
revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding

Su Mei Slim Patch’s expansion to international market. Actual results could
differ materially from the expectations reflected in such forward-looking
statements as a result of a variety of factors, including the risks associated
with the effect of changing economic conditions in The People’s Republic of
, variations in cash flow, reliance on collaborative retail partners and
on new product development, variations in new product development, risks
associated with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors detailed in
reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.

Source: newswire

comments powered by Disqus